F
1.26
-0.13 (-9.35%)
Previous Close | 1.39 |
Open | 1.38 |
Volume | 9,735 |
Avg. Volume (3M) | 46,470 |
Market Cap | 3,311,469 |
Price / Sales | 0.380 |
Price / Book | 0.380 |
52 Weeks Range | |
Earnings Date | 4 Nov 2024 - 19 Nov 2024 |
Operating Margin (TTM) | -698.85% |
Diluted EPS (TTM) | -73.91 |
Total Debt/Equity (MRQ) | 0.18% |
Current Ratio (MRQ) | 0.460 |
Operating Cash Flow (TTM) | -61.14 M |
Levered Free Cash Flow (TTM) | -39.31 M |
Return on Assets (TTM) | -61.97% |
Return on Equity (TTM) | -216.23% |
Market Trend
Short Term | Medium Term | ||
Industry | Diagnostics & Research (US) | Mixed | Mixed |
Diagnostics & Research (Global) | Mixed | Mixed | |
Stock | Fresh2 Group Limited | - | - |
AIStockmoo Score
0.6
Analyst Consensus | 0.0 |
Insider Activity | NA |
Price Volatility | 0.5 |
Technical Moving Averages | 2.5 |
Technical Oscillators | -0.5 |
Average | 0.63 |
Fresh2 Group Ltd is a biotechnology company. It focuses on early cancer screening and detection. The company markets and sells a multi-cancer screening and detection test that uses its innovative patented CDA technology and its proprietary CDA device. In addition to early cancer screening and detection, its CDA technology has demonstrated the potential to assist physicians in cancer diagnosis, prognosis, and recurrence. |
|
Sector | Healthcare |
Industry | Diagnostics & Research |
% Held by Institutions | 0.21% |
No data within this time range.
No data within this time range.
Date | Type | Details |
---|---|---|
17 Oct 2024 | Announcement | Fresh2 Group Ltd. Announces Receipt of Staff Delisting Determination from Nasdaq; Intends to Request A Hearing |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
Realized Profit | - |
Unrealized Profit | - |
Dividend Received 2024 | - |
Total Profit | - |
Avg. Return | - |
Quantity (Buy) | - |
Avg. Price (Buy) | - |
Quantity (Sold) | - |
Avg. Price (Sold) | - |